Literature DB >> 27158605

Safety of intravitreal quinupristin/dalfopristin in an animal model.

Veronica E Giordano1, Sergio E Hernandez-Da Mota2, Tania N Adabache-Guel1, Armando Castillejos-Chevez3, Sonia Corredor-Casas4, Samantha M Salinas-Longoria1, Rafael Romero-Vera1, Juan M Jimenez-Sierra1, Jose L Guerrero-Naranjo1, Virgilio Morales-Canton1.   

Abstract

AIM: To determine whether different intravitreal doses of quinupristin/dalfopristin lead to electroretinographic or histological changes in the rabbit retina over one month period after injection.
METHODS: Eighteen New Zealand white rabbits were divided into three treatment groups (groups 1 to 3) and different intravitreal doses of quinupristin/dalfopristin were tested in each group. The right eye was injected with the drug and the left eye received intravitreal injection of 5% dextrose water and served as control eye. The doses delivered to each group were 0.1 mg/0.1 mL, 1 mg/0.1 mL and 10 mg/0.1 mL. Simultaneous, bilateral, dark-adapted electroretinography and clinical images of both eyes were obtained in all groups before injection (baseline) and after 7, 14, 21 and 28d, followed by enucleation for histological examination.
RESULTS: Subjects in the group 1 showed no signs of toxicity in the electroretinogram when compared with groups 2 and 3 (Kruskall-Wallis test, P=0.000). By day 7, no electrical response to light stimuli was recorded in the treated eyes in groups 2 and 3, consistent with severe damage due to retinal toxicity. Light microscopy revealed no significant histopathological changes in the group 1, while rabbits in groups 2 and 3 had signs of granulomatous inflammation in most cases.
CONCLUSION: Intravitreal 0.1 mg/0.1 mL doses of quinupristin/dalfopristin do not lead to electroretinographic or histological signs of retinal toxicity compared with 1 mg/0.1 mL and 10 mg/0.1 mL in this rabbit model.

Entities:  

Keywords:  endophthalmitis; quinupristin/dalfopristin; retinal toxicity

Year:  2016        PMID: 27158605      PMCID: PMC4844051          DOI: 10.18240/ijo.2016.03.08

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  19 in total

1.  Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial.

Authors:  E Albrecht; J C Richards; T Pollock; C Cook; L Myers
Journal:  Br J Ophthalmol       Date:  2011-02-02       Impact factor: 4.638

2.  ISCEV Standard for full-field clinical electroretinography (2008 update).

Authors:  M F Marmor; A B Fulton; G E Holder; Y Miyake; M Brigell; M Bach
Journal:  Doc Ophthalmol       Date:  2008-11-22       Impact factor: 2.379

Review 3.  Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.

Authors:  Michael D Nailor; Jack D Sobel
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

4.  Quinupristin/dalfopristin in vancomycin-resistant Staphylococcus aureus endophthalmitis.

Authors:  Edward M Stroh
Journal:  Arch Ophthalmol       Date:  2012-10

5.  Long-term potency, sterility, and stability of vancomycin, ceftazidime, and moxifloxacin for treatment of bacterial endophthalmitis.

Authors:  Sachin Mehta; Brian K Armstrong; Stephen J Kim; Hassanain Toma; Janice N West; Huiyong Yin; Pengcheng Lu; Laura L Wayman; Franco M Recchia; Paul Sternberg
Journal:  Retina       Date:  2011 Jul-Aug       Impact factor: 4.256

6.  Intravitreal daptomycin: a safety and efficacy study.

Authors:  Grant M Comer; John B Miller; Eric W Schneider; Naheed W Khan; David M Reed; Victor M Elner; David N Zacks
Journal:  Retina       Date:  2011-06       Impact factor: 4.256

Review 7.  Combining quinupristin/dalfopristin with other agents for resistant infections.

Authors:  Jack Brown; Burgess B Freeman
Journal:  Ann Pharmacother       Date:  2004-02-27       Impact factor: 3.154

8.  Ocular toxicity of intravitreal trovafloxacin in the pigmented rabbit.

Authors:  Eugene W M Ng; Myung-Jin Joo; Kah-Guan Au Eong; W Richard Green; Terrence P O'Brien
Journal:  Curr Eye Res       Date:  2003-12       Impact factor: 2.424

9.  [Retinal toxicity of intravitreal doxycycline. A pilot study].

Authors:  E Aydin; A A Kazi; G A Peyman; M R Esfahani; A Muñoz-Morales; M Kivilcim; M Caro-Magdaleno
Journal:  Arch Soc Esp Oftalmol       Date:  2007-04

10.  Quinupristin/dalfopristin in Staphylococcus aureus endophthalmitis: a case report.

Authors:  Sergio E Hernandez-Da Mota
Journal:  J Med Case Rep       Date:  2011-03-31
View more
  2 in total

1.  Emerging Worldwide Antimicrobial Resistance, Antibiotic Stewardship and Alternative Intravitreal Agents for the Treatment of Endophthalmitis.

Authors:  Nidhi Relhan; Avinash Pathengay; Stephen G Schwartz; Harry W Flynn
Journal:  Retina       Date:  2017-05       Impact factor: 4.256

2.  Safety threshold of intravitreal clonidine in rabbit's eyes.

Authors:  Homayoun Nikkhah; Kiumars Heidari Garfami; Mozhgan Rezaei Kanavi; Ebrahim Mohammad Nashtaei; Saeed Karimi; Masoud Soheilian
Journal:  Int J Ophthalmol       Date:  2018-01-18       Impact factor: 1.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.